SPARC announces positive results from Phase 3 trial of PDP-716
The trial met its pre-specified primary endpoint, demonstrating that PDP-716 dosed once daily is equivalent to Alphagan P 0.1% dosed 3 times a day
The trial met its pre-specified primary endpoint, demonstrating that PDP-716 dosed once daily is equivalent to Alphagan P 0.1% dosed 3 times a day
The company has reported total income of Rs.19425.58 crores during FY ended March 31, 2021
The deal is to sell one of the two business undertakings of ZAHL for a lump sum consideration of Rs. 2921 crores on a cash free and debt free basis,
Eris Lifesciences has reported total income of Rs.1220.57 crores during the 12 months period ended March 31, 2021
The agreement will help ensure wider reach and access to patients in India
The additional allocation of Tocilizumab will ensure sufficient availability for COVID-19 patients and augment the government’s efforts to fight the pandemic
The rating withdrawal is based on the company’s request and in line with CRISIL Rating’s policy on withdrawal of ratings.
Alembic has reported total income of Rs.83.79 crores during the FY ended March 31, 2021
Baricitinib was issued a restricted emergency use approval by the Central Drugs Standard Control Organization (CDSCO)
Baricitinib is used in combination with remdesivir for the treatment of suspected or laboratory confirmed COVID-19
Subscribe To Our Newsletter & Stay Updated